Effie Tozzo, Chief Scientific Officer
Professional Overview
Effie Tozzo is an accomplished pharmaceutical and biotechnology executive with over 20 years of experience in drug development, translational sciences, and metabolic disease research. As the Chief Scientific Officer at Avilar Therapeutics, she is responsible for leading the company's scientific strategy, driving innovation, and overseeing the development of novel therapeutic solutions.
Experience Summary
Current Role
As the Chief Scientific Officer at Avilar Therapeutics, Effie Tozzo is responsible for shaping the company's scientific vision and guiding its drug development pipeline. She leverages her extensive expertise in metabolic diseases and translational research to advance Avilar's innovative therapies from the preclinical stage to clinical trials.
Career Progression
Prior to her current role, Effie held senior leadership positions at several prominent pharmaceutical and biotechnology companies. She served as the Senior Vice President of Drug Development at Cellarity, where she successfully led the company's efforts to advance its pipeline of cell-based therapies. Before that, she was the Senior Vice President of Translational Sciences at Mitobridge, Inc., where she played a pivotal role in the development of mitochondrial-targeted therapeutics. Effie's previous experience also includes roles at Merck, Roche, Bristol-Myers Squibb, and Millennium Pharmaceuticals, where she demonstrated her extensive knowledge in the areas of diabetes, endocrinology, and metabolic diseases.
Academic Background
Effie Tozzo holds a Ph.D. in Physiology and Biophysics from the University of Illinois at Chicago, where she specialized in the study of metabolic disorders and their underlying mechanisms.
Areas of Expertise
- Drug development and translational research
- Metabolic diseases, including diabetes and endocrinology
- In vivo pharmacology and preclinical studies
- Strategic leadership and team management
- Collaboration and cross-functional partnerships
Professional Impact
Throughout her career, Effie Tozzo has made significant contributions to the advancement of therapeutic solutions for metabolic disorders. She has successfully led the development of multiple drug candidates, several of which have progressed to clinical trials. Effie's expertise and leadership have been recognized by her peers, and she currently serves on the Board of Directors of CohBar, Inc., a biotechnology company focused on mitochondrial-based therapies.
Conclusion
Effie Tozzo is a highly respected and influential leader in the pharmaceutical and biotechnology industry, with a proven track record of driving scientific innovation and advancing the development of novel therapeutic solutions. As the Chief Scientific Officer at Avilar Therapeutics, she is well-positioned to leverage her extensive experience and expertise to guide the company's cutting-edge research and development efforts, ultimately improving patient outcomes in the field of metabolic diseases.
